Monday, February 9, 2009, 10:30AM/EST
The Waldorf-Astoria, New York City
**Presentation To Be Webcast**
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE Alternext US: NBY, http://novabaypharma.com), a biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial and viral infections, will present at the 11th Annual BIO CEO & Investor Conference, the largest investor conference focused on publicly traded biotech companies. The event will be held at the Astor Room in the Waldorf-Astoria in New York City on Monday, February 9, 2009, at 10:30AM/EST.
Dr. Ron Najafi, NovaBay’s Chief Executive Officer, will provide a corporate overview and highlight NovaBay’s business development strategy and product development candidates in the areas of hospital infections, catheter-associated urinary tract infections, and dermatology. Dr. Najafi will highlight NovaBay’s recent announcements concerning the clearance of an Investigational New Drug application (IND) submitted by Alcon to the FDA to permit the clinical development of NovaBay’s NVC-422 for infections of the eye; the issuance of a key composition of matter patent for the company’s lead Aganocide® antimicrobial compound, currently in Phase II clinical development; and patient enrollment in exploratory Phase II trial of the company’s lead aganocide compound, NVC-422, in catheter-associated urinary tract infections.
This presentation will also be made available via webcast at:
About the BIO CEO & Investor Conference
The BIO CEO & Investor Conference is the largest investor conference focused on publicly traded biotech companies. Because BIO’s mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. BIO’s therapeutic workshops feature the latest information on pipeline innovation, and no other investor conference offers as many sessions involving MDs, CSOs, and industry analysts. BIO’s One-on-One Partnering also provides an opportunity to arrange meetings between investors; companies; and industry BD, licensing and therapeutic franchise heads. For more information visit http://www.ceo.bio.org/opencms/ceo/2009/
About NovaBay® Pharmaceuticals
NovaBay® Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative non-antibiotic, antimicrobial product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay® has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocide® compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens, without ever developing resistance. NovaBay® believes that Aganocide® compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including resistant bacteria such as MRSA. NovaBay® has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide® compounds in the eye, ear and sinus, and in contact lens solutions. NovaBay® and Aganocide® are registered trademarks of NovaBay® Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson
The Investor Relations Group
Adam Holdsworth / James Carbonara
Janet Vasquez / Laura Colontrelle